PMID- 26452994
OWN - NLM
STAT- MEDLINE
DCOM- 20161020
LR  - 20181202
IS  - 1471-1753 (Electronic)
IS  - 0954-6634 (Linking)
VI  - 27
IP  - 3
DP  - 2016
TI  - Fumaric acid esters in recalcitrant pediatric psoriasis: A prospective, daily 
      clinical practice case series.
PG  - 214-20
LID - 10.3109/09546634.2015.1088131 [doi]
AB  - BACKGROUND: Evidence on fumaric acid esters (FAE) in the treatment of pediatric 
      psoriasis is scarce. OBJECTIVE: Describe the effectiveness, influence on the 
      quality of life (QoL) and safety of FAE in children with recalcitrant psoriasis 
      in daily clinical practice. METHODS: A prospective case series. RESULTS: Fourteen 
      patients with recalcitrant plaque-type psoriasis were described (mean age 13.7, 
      range 8-17 years). Mean treatment duration was 48.6 weeks (range 12-124). Maximum 
      daily dose varied between 180 and 1200 mg with a mean of 564 mg per day. Mean 
      Psoriasis Area and Severity Index (PASI) (+/-SEM) at baseline was 10.5 (1.0) 
      compared to 8.6 (1.1), 6.2 (1.6) and 4.9 (1.5) at week 12, 24 and 36, 
      respectively. An improvement in PASI was observed in nine patients (64.3%). Mean 
      CDLQI (+/-SEM) at week 0, 12, 24 and 36 was 8.9 (1.4), 6.8 (1.2), 3.7 (1.4) and 3.1 
      (2.0), respectively. Most common adverse events (AEs) were gastrointestinal 
      complaints (n = 13, 92.9%) and flushes (n = 10, 71.4%). Lymphocytopenia (n = 5, 
      45.5%) and eosinophilia (n = 4, 36.4%) were frequently observed laboratory 
      abnormalities. AEs were usually mild and transient. One serious adverse event, 
      unrelated to FAE, was reported. CONCLUSIONS: FAE showed improvement of disease 
      severity and QoL in the majority of children. Side-effects occurred frequently, 
      but were usually mild and transient. FAE may be an alternative systemic treatment 
      option for pediatric psoriasis, provided that also the long-term safety data are 
      closely monitored, in particular lymphocytopenia.
FAU - van Geel, M J
AU  - van Geel MJ
AD  - a Department of Dermatology , Radboud university medical center , Nijmegen , The 
      Netherlands.
FAU - van de Kerkhof, P C M
AU  - van de Kerkhof PC
AD  - a Department of Dermatology , Radboud university medical center , Nijmegen , The 
      Netherlands.
FAU - Oostveen, A M
AU  - Oostveen AM
AD  - a Department of Dermatology , Radboud university medical center , Nijmegen , The 
      Netherlands.
FAU - de Jong, E M G J
AU  - de Jong EM
AD  - a Department of Dermatology , Radboud university medical center , Nijmegen , The 
      Netherlands.
FAU - Seyger, M M B
AU  - Seyger MM
AD  - a Department of Dermatology , Radboud university medical center , Nijmegen , The 
      Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20151009
PL  - England
TA  - J Dermatolog Treat
JT  - The Journal of dermatological treatment
JID - 8918133
RN  - 0 (Dermatologic Agents)
RN  - FO2303MNI2 (Dimethyl Fumarate)
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Dermatologic Agents/adverse effects/*therapeutic use
MH  - Dimethyl Fumarate/adverse effects/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Prospective Studies
MH  - Psoriasis/*drug therapy/physiopathology/psychology
MH  - Quality of Life/psychology
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Children
OT  - daily clinical practice
OT  - dimethylfumarate
OT  - fumaric acid esters
OT  - juvenile
OT  - pediatric
OT  - psoriasis
OT  - systemic treatment
EDAT- 2015/10/11 06:00
MHDA- 2016/10/21 06:00
CRDT- 2015/10/11 06:00
PHST- 2015/10/11 06:00 [entrez]
PHST- 2015/10/11 06:00 [pubmed]
PHST- 2016/10/21 06:00 [medline]
AID - 10.3109/09546634.2015.1088131 [doi]
PST - ppublish
SO  - J Dermatolog Treat. 2016;27(3):214-20. doi: 10.3109/09546634.2015.1088131. Epub 
      2015 Oct 9.